Sickle cell disease (SCD) affects approximately 100,000 individuals in the United States. Vaso-occlusive crisis (VOC), characterized by the sudden onset of severe pain, is the most common reason for hospital visits in patients with SCD. However, despite the availability of guidelines on the recommended treatment, acute pain in SCD is often undertreated. Although opioids are recommended for severe acute pain episodes, the concern about addiction often results in clinicians failing to provide adequate pain control. Hydroxyurea is the only treatment that modifies the disease process in SCD; however, many providers are uncomfortable prescribing it, and many eligible patients with SCD remain inadequately treated.
Now, new therapies are becoming available, and clinicians have a greater need for education about the efficacy and safety data of established and novel treatments for the management and prevention of VOCs.
This activity will review the most recent clinical data and evidence-based updates and provide expert insights on preventing and reducing VOCs in sickle cell disease.